A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

Abstract Background This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA). Methods In this randomized, double-blind, active-controlled, non-inferiority tria...

Full description

Bibliographic Details
Published in:Arthritis Research & Therapy
Main Authors: Ahmadreza Jamshidi, Farhad Gharibdoost, Mahdi Vojdanian, Soosan G. Soroosh, Mohsen Soroush, Arman Ahmadzadeh, Mohammad Ali Nazarinia, Mohammad Mousavi, Hadi Karimzadeh, Mohammad Reza Shakibi, Zahra Rezaieyazdi, Maryam Sahebari, Asghar Hajiabbasi, Ali Asghar Ebrahimi, Najmeh Mahjourian, Amin Mohammadinejad Rashti
Format: Article
Language:English
Published: BMC 2017-07-01
Subjects:
Adalimumab
Biosimilar
CinnoRA®
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-017-1371-4

Internet

http://link.springer.com/article/10.1186/s13075-017-1371-4

Similar Items